Cybrexa, a spin-out company from Yale University, is developing a new class of cancer therapeutics, looking to identify combinations of chemotherapy and DNA inhibitors to increase efficacy and reduce toxicity in cancer treatment. Abi Millar spoke to the company to find out more about its approach to oncology.
